Cargando…
In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222403/ https://www.ncbi.nlm.nih.gov/pubmed/35765465 http://dx.doi.org/10.1016/j.xkme.2022.100503 |
| _version_ | 1784732865486913536 |
|---|---|
| author | Fernandes, Guillaume Devresse, Arnaud Scohy, Anais De Greef, Julien Yombi, Jean Cyr Belkhir, Leila Darius, Tom Mourad, Michel Buemi, Antoine Kabamba, Benoit Goffin, Eric Kanaan, Nada |
| author_facet | Fernandes, Guillaume Devresse, Arnaud Scohy, Anais De Greef, Julien Yombi, Jean Cyr Belkhir, Leila Darius, Tom Mourad, Michel Buemi, Antoine Kabamba, Benoit Goffin, Eric Kanaan, Nada |
| author_sort | Fernandes, Guillaume |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9222403 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92224032022-06-24 In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ Fernandes, Guillaume Devresse, Arnaud Scohy, Anais De Greef, Julien Yombi, Jean Cyr Belkhir, Leila Darius, Tom Mourad, Michel Buemi, Antoine Kabamba, Benoit Goffin, Eric Kanaan, Nada Kidney Med Correspondence Elsevier 2022-06-23 /pmc/articles/PMC9222403/ /pubmed/35765465 http://dx.doi.org/10.1016/j.xkme.2022.100503 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Correspondence Fernandes, Guillaume Devresse, Arnaud Scohy, Anais De Greef, Julien Yombi, Jean Cyr Belkhir, Leila Darius, Tom Mourad, Michel Buemi, Antoine Kabamba, Benoit Goffin, Eric Kanaan, Nada In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ |
| title | In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ |
| title_full | In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ |
| title_fullStr | In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ |
| title_full_unstemmed | In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ |
| title_short | In Reply to ‘Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations’ |
| title_sort | in reply to ‘kidney transplant recipients with covid-19 and monoclonal antibody therapy: additional considerations’ |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222403/ https://www.ncbi.nlm.nih.gov/pubmed/35765465 http://dx.doi.org/10.1016/j.xkme.2022.100503 |
| work_keys_str_mv | AT fernandesguillaume inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT devressearnaud inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT scohyanais inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT degreefjulien inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT yombijeancyr inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT belkhirleila inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT dariustom inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT mouradmichel inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT buemiantoine inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT kabambabenoit inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT goffineric inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations AT kanaannada inreplytokidneytransplantrecipientswithcovid19andmonoclonalantibodytherapyadditionalconsiderations |